Telix and United Imaging Partner to Advance AI-Driven Theranostics
MELBOURNE, Australia; INDIANAPOLIS, Indiana; and HOUSTON, Texas, June 2, 2026 Telix Pharmaceuticals and United Imaging Healthcare North America have...
theranostics
Advertisement
Curium Invests €32M to Expand Prostate Cancer RLT Production
PARIS, France, June 1, 2026 Curium, a global leader in radiopharmaceuticals and nuclear medicine, has announced a strategic investment...
Clarity Signs Deal to Boost Prostate Cancer Imaging Supply
Sydney, Australia | April 14, 2026 Clarity Pharmaceuticals has announced the signing of a Commercial Manufacturing Agreement with Nucleus...
Telix NDA Accepted for Pixclara Brain Cancer Imaging
Melbourne, Australia & Indianapolis, USA | April 10, 2026 Telix Pharmaceuticals has announced that the U.S. Food and Drug...
Cardinal Health Expands Ac-225 Supply for Cancer Therapies
Dublin, Ohio, USA – April 1, 2026 In a significant advancement for the rapidly evolving field of targeted cancer...
Advertisements
SECuRE Trial: Undetectable Disease With 67Cu-SAR-bisPSMA
SYDNEY, Australia, Feb. 23, 2026 — Clarity Pharmaceuticals announced a significant clinical milestone in the ongoing SECuRE Trial, reporting...
FAPI-74 Phase 3 Trial Doses First Pancreatic Patient
DULLES, Va., Feb. 11, 2026 — SOFIE Biosciences announced that the first patient has been dosed in its Phase...
Telix and Varian Launch Theranostics-EBRT Precision Oncology Collaboration
Melbourne, Australia & Palo Alto, CA – December 10, 2025 – Telix Pharmaceuticals Limited and Varian, a Siemens Healthineers...
Advertisement
